Enzene Biosciences, a subsidiary of Alkem Laboratories Ltd, plans a regulatory filing in the US for a biosimilar to Amgen, Inc.’s blockbuster osteoporosis drug Prolia (denosumab). Having tied up with Theramex for the European market and Australia, the move is a bid to expand the biosimilar’s geographical reach.
Scrip sat downwith CEO Himanshu Gadgil to discuss Enzene’s strategy, during which he spoke on a host of topics from revenue projections, the changing pricing and regulatory environment in the US and a strategic move to expand services to
The company currently derives about 80% of revenue from the domestic market and is aiming to up global sales
